Research location
Gahanna
Ohio, United States
Advertisement
Research activity in Gahanna
Ohio, United StatesCureCurrent currently publishes aggregate city-level research activity for this location: 39 trials and 40 site observations.
The map is centered on registry-derived city coordinates. Circle size reflects published trial activity.
Below are current trials with one or more ClinicalTrials.gov site observations in this city. Results are paginated 50 per page, with recruiting studies shown first.
Trials with sites in Gahanna
39 linked trials · page 1 of 1Study Comparing AAA817+ARPI Versus Standard of Care in Adult Participants With PSMA-positive mCRPCNCT06855277 · 2025-07-01 · 1 site observation
RECRUITING
Open-label Study Comparing AAA817 Versus Standard of Care in the Treatment of Previously Treated PSMA-positive mCRPC Adults Who Have Disease Progressed on or After [177Lu]Lu-PSMA Targeted TherapyNCT06780670 · 2025-02-27 · 1 site observation
RECRUITING
FK-PC101 as Adjuvant Therapy for Men With High-Risk Prostate CancerNCT06636682 · 2024-10-14 · 1 site observation
RECRUITING
A Study of Opevesostat (MK-5684) Versus Alternative Next-generation Hormonal Agent (NHA) in Metastatic Castration-resistant Prostate Cancer (mCRPC) Post One NHA (MK-5684-004)NCT06136650 · 2023-12-18 · 1 site observation
RECRUITING
Metastatic Castrate-Resistant Prostate Cancer Subjects Treated With PROVENGE® + One Infusion of Sipuleucel-TNCT06134232 · 2023-10-02 · 1 site observation
RECRUITING
Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer DetectionNCT05334069 · 2022-08-18 · 1 site observation
RECRUITING
Osimertinib With or Without Bevacizumab as Initial Treatment for Patients With EGFR-Mutant Lung CancerNCT04181060 · 2020-12-28 · 1 site observation
RECRUITING
Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])NCT04267848 · 2020-06-16 · 1 site observation
RECRUITING
Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary TumorsNCT03866382 · 2019-05-13 · 1 site observation
RECRUITING
Lung-MAP: A Master Screening Protocol for Previously-Treated Non-Small Cell Lung CancerNCT03851445 · 2019-02-06 · 1 site observation
RECRUITING
Developing an Internet-Delivered Sexual Health Program for Breast Cancer Survivors, SHINE TrialNCT06216574 · 2024-03-14 · 1 site observation
ACTIVE_NOT_RECRUITING
Cognitive Training for Cancer Related Cognitive Impairment in Breast Cancer SurvivorsNCT05896189 · 2024-02-29 · 1 site observation
ACTIVE_NOT_RECRUITING
A Study of an Intermittent ADT Approach With Apalutamide Monotherapy in Participants With mCSPCNCT05884398 · 2023-08-31 · 1 site observation
ACTIVE_NOT_RECRUITING
Randomized Study to Evaluate MACE in Patients With Prostate Cancer Treated With Relugolix or Leuprolide AcetateNCT05605964 · 2023-01-28 · 2 site observations
COMPLETED
A Study Called ARAMON to Learn to What Extent Does Study Treatment With Darolutamide Affects Testosterone Levels in Men With Prostate Cancer That Had Not Been Treated With Hormonal Therapy Compared to Treatment With EnzalutamideNCT05526248 · 2022-12-19 · 1 site observation
COMPLETED
A Multi-Center, Prospective, Observational Study of Patients Being Treated With ORGOVYXNCT05467176 · 2022-10-04 · 1 site observation
COMPLETED
177Lu-PSMA-I&T for Metastatic Castration-Resistant Prostate CancerNCT05204927 · 2022-02-14 · 1 site observation
ACTIVE_NOT_RECRUITING
A Study to Learn How Well Darolutamide Administered Together With Androgen Deprivation Therapy (ADT) Works in Men With Metastatic Hormone-sensitive Prostate Cancer. Results Will be Compared With ADT Alone From a Previously Conducted Study.NCT05059236 · 2021-11-04 · 1 site observation
COMPLETED
Testing the Use of Targeted Treatment (AMG 510) for KRAS G12C Mutated Advanced Non-squamous Non-small Cell Lung Cancer (A Lung-MAP Treatment Trial)NCT04625647 · 2021-04-16 · 1 site observation
ACTIVE_NOT_RECRUITING
T-DM1 and Tucatinib Compared With T-DM1 Alone in Preventing Relapses in People With High Risk HER2-Positive Breast Cancer, the CompassHER2 RD TrialNCT04457596 · 2021-03-02 · 1 site observation
ACTIVE_NOT_RECRUITING
Basket Study of Tucatinib and Trastuzumab in Solid Tumors With HER2 AlterationsNCT04579380 · 2021-01-11 · 1 site observation
ACTIVE_NOT_RECRUITING
NCI COVID-19 in Cancer Patients, NCCAPS StudyNCT04387656 · 2020-06-05 · 1 site observation
ACTIVE_NOT_RECRUITING
Testing the Addition of an Antibody to Standard Chemoradiation Followed by the Antibody for One Year to Standard Chemoradiation Followed by One Year of the Antibody in Patients With Unresectable Stage III Non-Small Cell Lung CancerNCT04092283 · 2020-04-29 · 1 site observation
ACTIVE_NOT_RECRUITING
Docetaxel or Paclitaxel in Reducing Chemotherapy-Induced Peripheral Neuropathy in African American Patients With Stage I-III Breast CancerNCT04001829 · 2019-08-09 · 1 site observation
ACTIVE_NOT_RECRUITING
Targeted Treatment for ALK Positive Patients Who Have Previously Been Treated for Non-squamous Non-small Cell Lung CancerNCT03737994 · 2019-07-25 · 1 site observation
TERMINATED
Effect of Treatment on Work Experience in Patients With Stage I-III Prostate CancerNCT03963739 · 2019-07-19 · 1 site observation
COMPLETED
An Open-label Study of Encorafenib + Binimetinib in Patients With BRAFV600-mutant Non-small Cell Lung CancerNCT03915951 · 2019-06-04 · 1 site observation
COMPLETED
Ramucirumab and Pembrolizumab Versus Standard of Care in Treating Patients With Stage IV or Recurrent Non-small Cell Lung Cancer (A Lung-MAP Non-Match Treatment Trial)NCT03971474 · 2019-05-28 · 1 site observation
COMPLETED
Rucaparib in Treating Patients With Genomic LOH High and/or Deleterious BRCA1/2 Mutation Stage IV or Recurrent Non-small Cell Lung Cancer (A Lung-MAP Treatment Trial)NCT03845296 · 2019-04-16 · 1 site observation
COMPLETED
Testing the Timing of Pembrolizumab Alone or With Chemotherapy as First Line Treatment and Maintenance in Non-small Cell Lung CancerNCT03793179 · 2019-04-05 · 1 site observation
ACTIVE_NOT_RECRUITING
Darolutamide in Addition to Standard Androgen Deprivation Therapy and Docetaxel in Metastatic Hormone-Sensitive Prostate CancerNCT02799602 · 2016-11-30 · 1 site observation
COMPLETED
Effectiveness of the Optifast Program Compared With a Reduced-energy Food Based Diet Plan on Body WeightNCT02635698 · 2015-11-01 · 1 site observation
COMPLETED
Efficacy and Safety Study of Darolutamide (ODM-201) in Men With High-risk Non-metastatic Castration-resistant Prostate CancerNCT02200614 · 2014-09-12 · 1 site observation
COMPLETED
Real-world Outcomes on Tecfidera (BG00012, Dimethyl Fumarate) Post-Tysabri (BG00002, Natalizumab)NCT02159573 · 2014-07-01 · 1 site observation
COMPLETED
Observational Study of Tysabri in Early Relapsing-Remitting Multiple Sclerosis in Anti-JC Virus Antibody Negative ParticipantsNCT01485003 · 2012-02-07 · 1 site observation
COMPLETED
Positive Imaging Study for Distant Metastases in Patients With Castration-Resistant Prostate CancerNCT01981109 · 2012-01-01 · 1 site observation
TERMINATED
JC Virus Antibody Study of Participants With Relapsing Forms of MS Receiving Treatment With NatalizumabNCT01070836 · 2010-03-01 · 1 site observation
COMPLETED
OMNI Study--Assessing Therapies in Medtronic Pacemaker, Defibrillator, and Cardiac Resynchronization Therapy Devices.NCT00277524 · 2005-08-01 · 1 site observation
TERMINATED
Expanded Access For Lorlatinib For Patients With Non Small Cell Lung Cancer ALK Positive or ROS1 PositiveNCT03178071 · 1 site observation
NO_LONGER_AVAILABLE
Advertisement
Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.